Search research articles
Contact Us
Filters
Showing results (101-110 of 124) with videos related to
Page
of 13
Sort By:
Nature
|
October 26, 2022
The co-evolution of the genome and epigenome in colorectal cancer
Timon Heide, Jacob Househam, George D Cresswell, et al.
British Journal of Cancer
|
July 6, 2021
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer
José J G Marin, Maria Giuseppina Prete, Angela Lamarca, et al.
British Journal of Cancer
|
July 23, 2020
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
José J G Marin, Maria Giuseppina Prete, Angela Lamarca, et al.
JAMA
|
March 16, 2026
Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial
Elske C Gootjes, Lotte Bakkerus, Anviti A Adhin, et al.
The Lancet. Oncology
|
March 30, 2019
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
John N Primrose, Richard P Fox, Daniel H Palmer, et al.
Future Oncology (London, England)
|
August 8, 2024
A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer
James J Harding, Jia Fan, Do-Youn Oh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial
Tanios S Bekaii-Saab, Davide Melisi, Hanneke Wilmink, et al.
The New England Journal of Medicine
|
February 2, 2022
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Yuichiro Doki, Jaffer A Ajani, Ken Kato, et al.
The Lancet. Oncology
|
May 17, 2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, et al.
Nature
|
October 26, 2022
Phenotypic plasticity and genetic control in colorectal cancer evolution
Jacob Househam, Timon Heide, George D Cresswell, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 124) with videos related to
Sort By:
Page
of 13
Nature
|
October 26, 2022
The co-evolution of the genome and epigenome in colorectal cancer
Timon Heide, Jacob Househam, George D Cresswell, et al.
British Journal of Cancer
|
July 6, 2021
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer
José J G Marin, Maria Giuseppina Prete, Angela Lamarca, et al.
British Journal of Cancer
|
July 23, 2020
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
José J G Marin, Maria Giuseppina Prete, Angela Lamarca, et al.
JAMA
|
March 16, 2026
Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial
Elske C Gootjes, Lotte Bakkerus, Anviti A Adhin, et al.
The Lancet. Oncology
|
March 30, 2019
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
John N Primrose, Richard P Fox, Daniel H Palmer, et al.
Future Oncology (London, England)
|
August 8, 2024
A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer
James J Harding, Jia Fan, Do-Youn Oh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial
Tanios S Bekaii-Saab, Davide Melisi, Hanneke Wilmink, et al.
The New England Journal of Medicine
|
February 2, 2022
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Yuichiro Doki, Jaffer A Ajani, Ken Kato, et al.
The Lancet. Oncology
|
May 17, 2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, et al.
Nature
|
October 26, 2022
Phenotypic plasticity and genetic control in colorectal cancer evolution
Jacob Househam, Timon Heide, George D Cresswell, et al.
Page
of 13